Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURSKUKHUSET I JÄGARVALLEN
Mandate

VINGE ADVISES ANICURA IN CONNECTION WITH THE ACQUISITION OF DJURSKUKHUSET I JÄGARVALLEN

November 18, 2014

Vinge has advised AniCura in connection with the acquisition of Djursjukhuset i Jägarvallen, the oldest veterinary clinic in the county of Östergötland. The merger entails that AniCura has broadened its base of veterinary and medical facilities for pet owners in the region. AniCura is a leader in advanced veterinary care for dogs, cats and other companion animals. The company was founded on the notion of combining resources to provide better veterinary care. Established in 2011, AniCura is the first merger of companion animal hospitals in the Nordic region, and is currently the only Nordic veterinary care group exclusively focused on companion animals.

Vinge’s team consisted of responsible partner Jonas Bergström together with, among others, associates Gustav Jönsson and Ulrika Andersson.   

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025